期刊文献+

蛋白别构机制及其在药物研发中的展望 被引量:1

Allosteric Regulation:Mechanism Study and Applications in Drug Discovery
原文传递
导出
摘要 别构调节(allosteric regulation)是指调节分子结合在正位活性位点(orthosteric site)以外的位点,诱导蛋白构象变化来调节蛋白活性位点功能。别构调节具有位点多样化、调节分子多元化、调节特异性高和调节效应有上限等优点,使其成为新兴药物开发的重要策略。已有很多研究人员针对现有靶点研发别构药物,与以往正位活性位点的竞争性药物相比,别构药物特异性更好,能够区分家族内的同源蛋白,副作用小,并且实现从别构位点至活性位点的远程通讯,能够和内源性配体同时结合靶蛋白协同发挥功能等优点。该文将从别构调节的发展历史、机制、研究方法、别构调节剂的研究进展及别构药物开发的未来展望作一简要综述。 Allosteric regulation is that allosteric modulator binds at an allosteric site, a site distinct from the orthosteric site, inducing the change in conformation of protein to regulate its function activity. Allosteric regulation has many advantages due to specific features of allosteric sites, including structural diversity and flexibility. Then allosteric modulators show high selectivity, low toxicity and a ceiling effect on target, which presents a novel approach to drug discovery. In addition, allosteric modulator is able to trigger the communication between their binding allosteric site and corresponding functional site, as well as act in synergy with cofactors or endogenous ligands. This review focuses on the history, mechanism, methods of allostery, the progress of allosteric modulators and the outlook of allosteric drugs in drug discovery.
作者 王承祥 张健 Wang Chengxiang Zhang Jian(Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, Chin)
出处 《中国细胞生物学学报》 CAS CSCD 2016年第12期1441-1450,共10页 Chinese Journal of Cell Biology
基金 国家自然科学基金(批准号:81322046)资助的课题~~
关键词 别构调节 别构蛋白 别构位点 别构调节剂 别构药物 allostery allosteric protein allosteric site allosteric modulators allosteric drug
  • 相关文献

参考文献1

二级参考文献12

  • 1Weinberg RA. The retinoblastoma protein and cell cycle control[ J]. Cell, 1995, 81(3): 323-330.
  • 2Morgan DO. Principle of CDK regulation [ J ]. Nature, 1995, 374 (6518): 131 -134.
  • 3Errico A, Deshmukh K, Tanaka Y, et ai. Identification of substrates for cyclin dependent kinases l[J]. Adv Enzyme Regu, 2010, 50 (1): 375 - 399.
  • 4Betzi S, Alam B., Martin M, et al. Discovery of a potential anosteric ligand binding site in CDK2[J]. ACS Chem Biol, 2011, 6(5): 492 - 501.
  • 5Martin MP, Alam R, Betzi S, et al. A novel approach to the discovery of small-molecule ligands of CDK2 [ J ]. Chembiochem, 2012, 13 (14): 2128-2136.
  • 6Karthiga A, Tripathi SK, Shanmugam R, et al. Targeting the cyclin-binding groove site to inhibit the catalytic activity of CDK2/ cyclin A complex using p27KIPl-derived peptidomimetic inhibitors [J]. J Chem Biol, 2015, 8(1): 11 -24.
  • 7Christopoulos A, May LT, Avlani VA, et al. G-protein-coupled receptor allosterism : the promise and the problem (s) [ J ]. Biochem Soc Trans, 2004, 32 ( Pt 5) : 873 - 877.
  • 8Hu Y, Li S, Liu F, et al. Discovery of novel nonpeptide allosteric inhibitors interrupting the interaction of CDK2/cyclin A3 by virtual screening and bioassays [ J]. Bioorg Med Chem Lett, 2015, 25 (19) : 4069 -4073.
  • 9Berman HM, Westbrook J, Feng Z, et al. The protein data bank [J]. Nucleic Acids Res, 2000, 28(1): 235-242.
  • 10Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy[J]. J Med Chem, 2004, 47(7): 1739-1749.

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部